NCT00517387 - The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Unipolar Depression

Interventions

DRUG

Quetiapine XR

All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.

Trial Locations (1)

V6T 2A1

University of British Columbia Hospital, Vancouver